HBIO Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
22.2M
-2.3%
22.7M
+9.5%
20.8M
-12.6%
23.7M
+15.3%
20.6M
Cost of Revenue
9.9M
-2.1%
10.1M
+18.6%
8.5M
-11.0%
9.6M
+11.6%
8.6M
Gross Profit
12.3M
-2.6%
12.6M
+3.2%
12.2M
-13.6%
14.2M
+17.9%
12.0M
Operating Expenses
13.5M
-1.1%
13.6M
+1.4%
13.4M
+7.7%
12.5M
+5.4%
11.8M
R&D
2.3M
-7.9%
2.5M
+5.5%
2.3M
+6.6%
2.2M
+2.4%
2.1M
SG&A
10.2M
+1.6%
10.0M
-0.2%
10.0M
+9.0%
9.2M
+4.8%
8.8M
Operating Income
-1150000
-17.6%
-978000
+16.7%
-1174000
-168.7%
1.7M
+768.0%
197.0K
EBITDA
-198000
-149.9%
397.0K
+125.6%
176.0K
-94.2%
3.1M
+101.2%
1.5M
Net Income
-2623000
+9.9%
-2910000
+15.0%
-3424000
-20.3%
-2847000
-131.3%
-1231000
EPS (Basic)
$-0.58
+9.4%
$-0.64
+16.9%
$-0.77
-20.3%
$-0.64
-128.6%
$-0.28
EPS (Diluted)
$-0.58
+9.4%
$-0.64
+16.9%
$-0.77
-20.3%
$-0.64
-128.6%
$-0.28
Shares (Diluted)
4.6M
+0.8%
4.5M
+1.2%
4.5M
+0.3%
4.5M
+0.1%
4.5M
Harvard Bioscience (HBIO) — Financials